FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016123004> ?p ?o ?g. }

• W2016123004 endingPage "33" @default.
• W2016123004 startingPage "28" @default.
• W2016123004 abstract "PSA doubling time (PSADT) is an attractive intermediate end point for assessing novel therapies in biochemically recurrent prostate cancer (BRPC). This study explores whether PSADT calculations are influenced by frequency/duration of PSA measurements, and whether statistical variability leads investigators to find false significant results. In retrospective analyses of two BRPC cohorts: Johns Hopkins Hospital (JHH) patients who deferred therapy and placebo patients on a randomized clinical trial (RCT), we calculated changes in PSADT from early measurements to later measurements using subsets of available PSAs for patients with ⩾6 and ⩾9 PSAs. We simulated hypothetical single-arm trials using randomly selected, 50-patient subsets and simulated two-arm RCTs. JHH cohort (n=205) had median follow-up 58 months, median age 61 years and median Gleason 7. PSA variability changed with duration of PSA measurement as median within-patient PSADT increases for men with >6 PSAs ranged from 1.0 to 1.4 months by PSA subset while increases for men with ⩾9 PSAs ranged from 3.9 to 4.1 months. Frequency of measurement did not change PSA variability as PSADT increase was unchanged when odd values were used instead of all values. Approximately 30% of JHH men experienced >200% increases in PSADT. Up to 62% of 50-patient single-arm simulations detected a significant PSADT change, whereas simulated RCTs did not. Results were supported in the RCT placebo cohort; 46% of patients experienced PSADT increases >200%. These data suggest that calculated PSADT in BRPC may naturally increase over time in the absence of therapy and may be influenced by duration of PSA follow-up. As a result, single-arm trials could show false significant increases despite the lack of active treatment of these patients. Placebo-controlled RCTs including clinical end points are recommended to screen novel agents in men with BRPC to mitigate bias because of natural PSADT variability." @default.
• W2016123004 created "2016-06-24" @default.
• W2016123004 creator A5000484891 @default.
• W2016123004 creator A5001771354 @default.
• W2016123004 creator A5001783218 @default.
• W2016123004 creator A5007801126 @default.
• W2016123004 creator A5012074439 @default.
• W2016123004 creator A5015144369 @default.
• W2016123004 creator A5018645768 @default.
• W2016123004 creator A5025578214 @default.
• W2016123004 creator A5088048189 @default.
• W2016123004 date "2013-10-08" @default.
• W2016123004 modified "2023-10-17" @default.
• W2016123004 title "The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer" @default.
• W2016123004 cites W1506304343 @default.
• W2016123004 cites W1810097221 @default.
• W2016123004 cites W1982725736 @default.
• W2016123004 cites W2022282235 @default.
• W2016123004 cites W2036157478 @default.
• W2016123004 cites W2039892398 @default.
• W2016123004 cites W2065120184 @default.
• W2016123004 cites W2071879495 @default.
• W2016123004 cites W2079361452 @default.
• W2016123004 cites W2098047873 @default.
• W2016123004 cites W2099633587 @default.
• W2016123004 cites W2104870101 @default.
• W2016123004 cites W2107671263 @default.
• W2016123004 cites W2139295697 @default.
• W2016123004 cites W3023689102 @default.
• W2016123004 doi "https://doi.org/10.1038/pcan.2013.40" @default.
• W2016123004 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3945997" @default.
• W2016123004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24100642" @default.
• W2016123004 hasPublicationYear "2013" @default.
• W2016123004 type Work @default.
• W2016123004 sameAs 2016123004 @default.
• W2016123004 citedByCount "16" @default.
• W2016123004 countsByYear W20161230042014 @default.
• W2016123004 countsByYear W20161230042015 @default.
• W2016123004 countsByYear W20161230042016 @default.
• W2016123004 countsByYear W20161230042017 @default.
• W2016123004 countsByYear W20161230042018 @default.
• W2016123004 countsByYear W20161230042020 @default.
• W2016123004 countsByYear W20161230042021 @default.
• W2016123004 crossrefType "journal-article" @default.
• W2016123004 hasAuthorship W2016123004A5000484891 @default.
• W2016123004 hasAuthorship W2016123004A5001771354 @default.
• W2016123004 hasAuthorship W2016123004A5001783218 @default.
• W2016123004 hasAuthorship W2016123004A5007801126 @default.
• W2016123004 hasAuthorship W2016123004A5012074439 @default.
• W2016123004 hasAuthorship W2016123004A5015144369 @default.
• W2016123004 hasAuthorship W2016123004A5018645768 @default.
• W2016123004 hasAuthorship W2016123004A5025578214 @default.
• W2016123004 hasAuthorship W2016123004A5088048189 @default.
• W2016123004 hasBestOaLocation W20161230041 @default.
• W2016123004 hasConcept C121608353 @default.
• W2016123004 hasConcept C126322002 @default.
• W2016123004 hasConcept C126894567 @default.
• W2016123004 hasConcept C141071460 @default.
• W2016123004 hasConcept C142724271 @default.
• W2016123004 hasConcept C168563851 @default.
• W2016123004 hasConcept C185592680 @default.
• W2016123004 hasConcept C202751555 @default.
• W2016123004 hasConcept C204787440 @default.
• W2016123004 hasConcept C27081682 @default.
• W2016123004 hasConcept C2776235491 @default.
• W2016123004 hasConcept C2779466945 @default.
• W2016123004 hasConcept C2780192828 @default.
• W2016123004 hasConcept C48900799 @default.
• W2016123004 hasConcept C55493867 @default.
• W2016123004 hasConcept C71924100 @default.
• W2016123004 hasConcept C72563966 @default.
• W2016123004 hasConceptScore W2016123004C121608353 @default.
• W2016123004 hasConceptScore W2016123004C126322002 @default.
• W2016123004 hasConceptScore W2016123004C126894567 @default.
• W2016123004 hasConceptScore W2016123004C141071460 @default.
• W2016123004 hasConceptScore W2016123004C142724271 @default.
• W2016123004 hasConceptScore W2016123004C168563851 @default.
• W2016123004 hasConceptScore W2016123004C185592680 @default.
• W2016123004 hasConceptScore W2016123004C202751555 @default.
• W2016123004 hasConceptScore W2016123004C204787440 @default.
• W2016123004 hasConceptScore W2016123004C27081682 @default.
• W2016123004 hasConceptScore W2016123004C2776235491 @default.
• W2016123004 hasConceptScore W2016123004C2779466945 @default.
• W2016123004 hasConceptScore W2016123004C2780192828 @default.
• W2016123004 hasConceptScore W2016123004C48900799 @default.
• W2016123004 hasConceptScore W2016123004C55493867 @default.
• W2016123004 hasConceptScore W2016123004C71924100 @default.
• W2016123004 hasConceptScore W2016123004C72563966 @default.
• W2016123004 hasIssue "1" @default.
• W2016123004 hasLocation W20161230041 @default.
• W2016123004 hasLocation W20161230042 @default.
• W2016123004 hasLocation W20161230043 @default.
• W2016123004 hasLocation W20161230044 @default.
• W2016123004 hasOpenAccess W2016123004 @default.
• W2016123004 hasPrimaryLocation W20161230041 @default.
• W2016123004 hasRelatedWork W108895284 @default.
• W2016123004 hasRelatedWork W1967410728 @default.
• W2016123004 hasRelatedWork W1968083949 @default.

• next